FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a T-cell receptor (TCR) having binding activity with a FMNKFIYEI-HLA A0201 complex, as well as a conjugate, a polyvalent complex and a composition containing same. Also disclosed is a nucleic acid molecule coding said TCR, as well as a vector and a cell containing same. Invention also relates to a method of producing a TCR having binding activity with the FMNKFIYEI-HLA A0201 complex, which involves culturing said cell.
EFFECT: invention is effective for treating liver cancer.
19 cl, 17 dwg, 4 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| T-CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN p53 | 2020 |
|
RU2830061C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2835543C1 |
